The utilization of adoptive transfer of in vitro expanded iNKT cells has been explored in both murine models and patients with hematological malignancies Tables 2, 3 (162–170) Figure 2 given the fact that it is feasible to expand iNKT cells in vitro and iNKT cells have inherent antitumor activity against CD1d cancer cells as well as immunosuppressing immune cells such as macrophages in TME (2, 4, 5, 140). This evidence concerns the gene CD1D and hematologic disorder.